Ceralasertib (AZD6738)

For research use only. Not for use in humans.

目录号：S7693

Ceralasertib (AZD6738) Chemical Structure

CAS No. 1352226-88-0

Ceralasertib (AZD6738) 是一种口服具有活性的，选择性 ATR 激酶抑制剂，IC50 为 1 nM。Phase 1/2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2432.43	现货
5mg	RMB 1615.57	现货
25mg	RMB 5700.55	现货
100mg	RMB 12039.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ceralasertib (AZD6738)发表文献67篇：

Cancer Cell, 2022, S1535-6108(21)00662-0

PubMed: 35051357 ( click the link to review the publication )

Cell, 2021, 184(25):6119-6137.e26

PubMed: 34890551 ( click the link to review the publication )

Cancer Cell, 2020, 15 pii: S1535-6108(20)30164-1

PubMed: 32359397 ( click the link to review the publication )

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Cancer Cell, 2017, 32(5):624-638

PubMed: 29056426 ( click the link to review the publication )

Dev Cell, 2022, 57(5):638-653.e5

PubMed: 35245445 ( click the link to review the publication )

Cancer Res, 2022, canres.1707.2021

PubMed: 35022212 ( click the link to review the publication )

Gastroenterology, 2021, S0016-5085(21)03281-9

PubMed: 34303658 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00315-4

PubMed: 33961796 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4917

PubMed: 34389714 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab785

PubMed: 34500463 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab643

PubMed: 34320214 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(17)e2024258118

PubMed: 33879618 ( click the link to review the publication )

Theranostics, 2021, 11(4):1795-1813

PubMed: 33408782 ( click the link to review the publication )

Cell Rep, 2021, 37(9):110060

PubMed: 34852220 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2021, S2352-345X(21)00249-6

PubMed: 34896285 ( click the link to review the publication )

Cancers (Basel), 2021, 13(24)6215

PubMed: 34944835 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3790

PubMed: 34359691 ( click the link to review the publication )

Free Radic Biol Med, 2021, 164:34-43

PubMed: 33418109 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):201

PubMed: 34349107 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00400-1

PubMed: 34525344 ( click the link to review the publication )

Sci Signal, 2021, 14(714):eaba2611

PubMed: 34932373 ( click the link to review the publication )

Sci Signal, 2021, 14(705):eabc4764

PubMed: 34665642 ( click the link to review the publication )

Cancer Sci, 2021, 112(11):4444-4456

PubMed: 34382294 ( click the link to review the publication )
J Leukoc Biol, 2021, 10.1002/JLB.2MA0321-064R

PubMed: 33884660 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(4)1504

PubMed: 33546122 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7077

PubMed: 33782497 ( click the link to review the publication )

Med Phys, 2021, 48(6):3243-3261

PubMed: 33837540 ( click the link to review the publication )

Transl Oncol, 2021, 14(9):101147

PubMed: 34118569 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):38

PubMed: 33824328 ( click the link to review the publication )

Nat Cell Biol, 2020, 1

PubMed: 32483388 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1):e000340

PubMed: 32461345 ( click the link to review the publication )

Cancer Res, 2020, 10;canres.57.2020

PubMed: 32522823 ( click the link to review the publication )

Haematologica, 2020, Online ahead of print

PubMed: 33054116 ( click the link to review the publication )

mBio, 2020, 11(1)

PubMed: 32071277 ( click the link to review the publication )

Cells, 2020, 9(11)E2452

PubMed: 33182724 ( click the link to review the publication )

PLoS Genet, 2020, 16(11):e1009176

PubMed: 33137164 ( click the link to review the publication )

DNA Repair (Amst), 2020, 87:102803

PubMed: 31991288 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(24)E9715

PubMed: 33352723 ( click the link to review the publication )

Cell Rep, 2020, 32(6):108018

PubMed: 32783940 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Mol Cell, 2019, 74(6):1123-1137

PubMed: 31053472 ( click the link to review the publication )

Genes Dev, 2019, 33(19-20):1397-1415

PubMed: 31467087 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1518-1532

PubMed: 30726735 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Front Oncol, 2019, 9:16

PubMed: 30761268 ( click the link to review the publication )
J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Open Biol, 2019, 9(9):190156

PubMed: 31506018 ( click the link to review the publication )

Biosci Rep, 2019, 39(9)

PubMed: 31471531 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.215210

PubMed: 31727767 ( click the link to review the publication )

Mutat Res, 2019, 816-818:111678

PubMed: 31557599 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1346

PubMed: 30087144 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):205

PubMed: 30157958 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29263259 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(7):1307-1316

PubMed: 30094103 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Radiat Res, 2018, 189(5):505-518

PubMed: 29474155 ( click the link to review the publication )

Nat Commun, 2017, 8:14728

PubMed: 28317845 ( click the link to review the publication )

Br J Cancer, 2017, 117(1):113-123

PubMed: 28535155 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15511

PubMed: 29138515 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112942-112958

PubMed: 29348879 ( click the link to review the publication )

Sci Rep, 2017, 7:41950

PubMed: 28176818 ( click the link to review the publication )

J Dermatol Sci, 2016, 84(3):239-247

PubMed: 27743911 ( click the link to review the publication )

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

产品描述

Ceralasertib (AZD6738) 是一种口服具有活性的，选择性 ATR 激酶抑制剂，IC50 为 1 nM。Phase 1/2。

靶点

ATR ^[1]
(Cell-free assay)

1 nM

体外研究

在四个Kras突变细胞系：H23，H460，A549，和H358中，AZD6738抑制ATR激酶活性，并损害细胞活性。在ATM缺失的H23细胞中，AZD6738强烈增强顺铂诱导快速细胞死亡的作用。^[1]在p53 或 ATM缺失的细胞中，AZD6738治疗引起复制叉停滞和未修复DNA损伤的积累，导致有丝分裂障碍，从而使细胞死亡。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
LICR-LON-HN4 and LICR-LON-HN5 cells	MUnGeY5kfGmxbjDhd5NigQ>?	Ml;0NE4xOyxiMD6xMEAxNjNuIEGsJFMtKDFyIN88US=>		NWrlVIVoSVqGNkezPEBqdmirYnn0bY9vKG:oIFHUVkB1cHKxdXfoJIxwe3Nib3[g[I94dnO2cnXhcUBxcG:\|cHjvdplt[XSrb36gc4YhS0iNMTDvckBU\XJ\|NEWu	NF\n[Zc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC1O\|g6OCd-M{CwOVc5QTB:L3G+
K8484 cells	NUPHfXdiTnWwY4Tpc44h[XO\|YYm=	NHTTU2QzKM7:TR?=	NWDGUpViPyCqb4Xydy=>	MlG4TY4hUzh2OESgZ4VtdHNuIFHaSFY4OzhiYYSgNkDDvU1iY3;tdIxmfGWueTDwdoV3\W62ZXSg[4Vu[2m2YXLpcoUucW6mdXPl[EBEcGtzIIDoc5NxcG:{eXzheIlwdiCxbjDT[ZJqdmViM{S1MEB1cGViZH;3cpN1emWjbTDBWHIhfGG{Z3X0Mi=>	NFXFbVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi5NVQ5QCd-Mkm4PVE1QDh:L3G+
SNU-601 cells	MXHD[YxtKGe{b4f0bEBqdmirYnn0bY9vKGG\|c3H5	M3W2U\|AuOSEQvH3vcE9N	M2rDVVUh\GG7cx?=	M4rNS3Rp\SCVIHHu[EB{fWJvR{GgdI9xfWyjdHnvcpMhd2ZiU17VMVYxOSClZXzsd{B4\XKnIHTyZY1ifGmlYXzsfUBidmRiZH;z[U1l\XCnbnTlcpRtgSCrbnPy[YF{\WRiYomgRXpFPjd\|OD6=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF\|OECzOEc,OjhzM{iwN\|Q9N2F-
breast cancer cell lines	M1jVVWNmdGxiZ4Lve5RpKGmwaHnibZRqd25iYYPzZZk>	NF7aXncxNjF{NTygNE4zPSxiMD61JIFv\CBzLkCg{txO	NFXN[nU2KGSjeYO=	M2jrd2lEPTBidnHseYV{KHKjbnfl[EBnem:vIECuN{B1dyB-MTFOwI1wdC:O	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzVyMUGxN{c,Ojd3MEGxNVM9N2F-
LoVo cells	M4fJO2Z2dmO2aX;uJIF{e2G7		NWTiO\|V7OjRiaB?=	MWPS[YR2[3Srb36gbY4h[2WubDDjc5VvfDtiYTDwdo9xd3K2aX;uJI9nKHSqZTDj[YxtKHCxcIXsZZRqd25iYYLlJEhqdiCjZHTpeIlwdiC2bzDj[YxtKGO7Y3zlJIFzemW\|dDmgeY5l\XKpb3nu[{BieG:ydH;zbZMhf2inbjDlfJBwe2WmIITvJIRzfWdiYYSgZ49v[2WwdILheIlwdnNiZ4LlZZRmeiC2aHHuJFPjiIoQvF2=	NGWwSXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOxNFMyOid-Mk[zNVA{OTJ:L3G+
HT29 cells	Mm\VSpVv[3Srb36gZZN{[Xl?		MYK2NEBucW6\|	M2TmSWlEPTBiPTCwMlA4PCEQvF2=	MlnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NE[3O\|IoRjNyM{S2O\|czRC:jPh?=
LoVo cells	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=		NIK0dlI4OiCqcoO=	NGXPOXRIUTVyIE2gNE41PCEQvF2=	NULpcWZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN\|Q3Pzd{PD;hQi=>
LoVo cells	MnzGSpVv[3Srb36gZZN{[Xl?	NXfsWYl{OjVibXevb4c>	NXq5V29mQCCqcoO=	NEfCSFdEeCB;IECuO\|Qh\|ryP	NWTLOXlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN\|Q3Pzd{PD;hQi=>
LoVo cells	MVrGeY5kfGmxbjDhd5NigQ>?	M2XTcFUxKG2pL3vn	Ml:2PEBpenN?	M1HJNWNxKD1iMj6yJO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2Nke3Nkc,OzB\|NE[3O\|I9N2F-
HT-29 cells	NVrXe5JXS3m2b4TvfIlkcXS7IHHzd4F6		NHr0T5M4OiCqcoO=	MXfHTVUxKD1iMj62JO69VQ>?	MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NE[3O\|IoRjNyM{S2O\|czRC:jPh?=
LoVo cells	MVPGeY5kfGmxbjDhd5NigQ>?	MWe3OUBu\y:tZx?=	MUG4JIhzew>?	MlzVR5AhRSB{Lk[g{txO	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2Nke3Nkc,OzB\|NE[3O\|I9N2F-
MDA-MB-468 cells	MX7GeY5kfGmxbjDhd5NigQ>?			M4DzUWlEPTBiPTC1Mlch\|ryP	NFXqcoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0Olc4Oid-M{CzOFY4PzJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATM pSer1981 / ATM / ATR / Chk1 pSer345 / Chk1 / Chk2 pThr68 / Chk2; PubMed: 26563132 Blood TP53/ATM wild-type (TP53/ATM-wt) primary CLL cells cocultured with and CLL cells, both CII-GFPsh and CII-ATMsh were treated with AZD6738 (1 μM) for 2 hours, or left untreated, prior to exposure to HU (1 mM) or IR (6 Gy) for a further 5 hours. AZD6738 treatment inhibited ATR signaling as indicated by a reduction in HU-induced Chk1 phosphorylation (lanes 3 vs 4 and 9 vs 10). In ATM-proficient CLL cells, this also led to ATM activation as evidenced by ATM phosphorylation and Chk2 phosphorylation (lane 3 vs 4). pCHK1 / pCDC25c / pRPA32 / γH2AX / pHH3 / cleaved caspase-3 / RAD51; PubMed: 29605721 Neoplasia MDA-231 or Hs578t cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. After treatment, western blot was performed using anti-γH2AX, anti-pCHK1 (S345), anti-CHK1, anti-pCDC25c (S216), anti-CDC25c, anti-pHH3, anti-RAD51 anti-pRPA32 (S4/S8), anti-cleaved-caspase 3, and anti-GAPDH antibodies.	26563132 29605721
Immunofluorescence	53BP1; PubMed: 26563132 Blood Cells treated with AZD6738 (1 μM) for 48 hours were labeled with anti-53BP1 antibodies, and at least 200 cells were then analyzed in each sample using a ×60 lens. AZD6738 treatment led to an accumulation of 53BP1 foci in Mec1 and ATMi pretreated CII cells and an accumulation of 53BP1 bodies in CII cells without ATMi pretreatment. γH2AX / RAD51; PubMed: 29605721 Neoplasia MDA-231 cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. Cells were probed with anti-γH2AX and anti-RAD51 antibodies. Scale bar: 5 μm.	26563132 29605721
Growth inhibition assay	IC50; PubMed: 28062704 Mol Cancer Ther Cell line IC50 values assessed for growth inhibition in a 72-hour MTT assay Cell viability; PubMed: 26563132 Blood CII-GFPsh, CII-ATMsh (ATM-deficient), and Mec1 (p53-defective) cells were treated with AZD6738 for 4 days, and viability was measured using the CellTiter-Glo assay. Surviving fraction is expressed relative to untreated controls. AZD6738 induced significantly greater dose-dependent cytotoxicity with significantly lower AZD6738 EC50 in CII-ATMsh and Mec1 cells compared with CII-GFPsh cells.	28062704 26563132

体内研究

在负荷H460和H23肿瘤的裸鼠中，AZD6738 (50 mg/kg, p.o.)导致肿瘤生长抑制(TGI)，结合顺铂引起ATM缺失的H23肿瘤快速退化。^[1]在负荷LoVo异种移植物的裸鼠中，AZD6738 (50 mg/kg) + IR (2 Gy)的组合避免了毒性，同时仍保持疗效。^[3]

细胞实验：^[1]	- 合并 Cell lines: H23，H460，A549，和 H358 细胞 Concentrations: ~30 μM Incubation Time: 48小时 Method: 细胞在白色壁，透明底的96孔板中与指示剂量的AZD6738，cisplatin，gemcitabine，或它们的组合处理48小时。ATP水平通过CellTiter-Glo发光细胞活性试验和Safire2酶标仪测量代替品活性评估。进一步分析之前，原始数据对本底发光进行校正。对于AZD6738治疗，在GraphPad Prism 6中将对数转化(x=log(x))的数据归一化为未处理对照组的平均值，通过非线性回归(log(抑制剂) vs. 对可变斜率的响应值) 生成对数剂量响应曲线。GI50值，定义为Y = 50%时，X的剂量，根据剂量反应曲线推导得出。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 负荷 H23 或 H460 异种移植物的雌性无胸腺裸鼠 Dosages: 25 或 50 mg/kg Administration: p.o. (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	82 mg/mL (198.78 mM)
	Water	Insoluble
	Ethanol	'41 mg/mL warmed
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% propylene glycol+ddH2O	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ceralasertib (AZD6738) SDF

分子量	412.51
化学式	C₂₀H₂₄N₆O₂S
CAS号	1352226-88-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04704661	Recruiting	Drug: Ceralasertib\|Biological: Trastuzumab Deruxtecan	Advanced Breast Carcinoma\|Advanced Colon Carcinoma\|Advanced Colorectal Carcinoma\|Advanced Endometrial Carcinoma\|Advanced Gastric Carcinoma\|Advanced Gastroesophageal Junction Adenocarcinoma\|Advanced Malignant Solid Neoplasm\|Advanced Salivary Gland Carcinoma\|Anatomic Stage III Breast Cancer AJCC v8\|Anatomic Stage IIIA Breast Cancer AJCC v8\|Anatomic Stage IIIB Breast Cancer AJCC v8\|Anatomic Stage IIIC Breast Cancer AJCC v8\|Anatomic Stage IV Breast Cancer AJCC v8\|Clinical Stage III Gastric Cancer AJCC v8\|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IV Gastric Cancer AJCC v8\|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IVA Gastric Cancer AJCC v8\|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IVB Gastric Cancer AJCC v8\|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8\|HER2-Positive Breast Carcinoma\|Malignant Hepatobiliary Neoplasm\|Metastatic Breast Carcinoma\|Metastatic Gastroesophageal Junction Adenocarcinoma\|Metastatic Malignant Solid Neoplasm\|Pathologic Stage III Gastric Cancer AJCC v8\|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIA Gastric Cancer AJCC v8\|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIB Gastric Cancer AJCC v8\|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIC Gastric Cancer AJCC v8\|Pathologic Stage IV Gastric Cancer AJCC v8\|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8\|Prognostic Stage III Breast Cancer AJCC v8\|Prognostic Stage IIIA Breast Cancer AJCC v8\|Prognostic Stage IIIB Breast Cancer AJCC v8\|Prognostic Stage IIIC Breast Cancer AJCC v8\|Prognostic Stage IV Breast Cancer AJCC v8\|Stage III Colon Cancer AJCC v8\|Stage III Colorectal Cancer AJCC v8\|Stage III Major Salivary Gland Cancer AJCC v8\|Stage III Uterine Corpus Cancer AJCC v8\|Stage IIIA Colon Cancer AJCC v8\|Stage IIIA Colorectal Cancer AJCC v8\|Stage IIIA Uterine Corpus Cancer AJCC v8\|Stage IIIB Colon Cancer AJCC v8\|Stage IIIB Colorectal Cancer AJCC v8\|Stage IIIB Uterine Corpus Cancer AJCC v8\|Stage IIIC Colon Cancer AJCC v8\|Stage IIIC Colorectal Cancer AJCC v8\|Stage IIIC Uterine Corpus Cancer AJCC v8\|Stage IIIC1 Uterine Corpus Cancer AJCC v8\|Stage IIIC2 Uterine Corpus Cancer AJCC v8\|Stage IV Colon Cancer AJCC v8\|Stage IV Colorectal Cancer AJCC v8\|Stage IV Major Salivary Gland Cancer AJCC v8\|Stage IV Uterine Corpus Cancer AJCC v8\|Stage IVA Colon Cancer AJCC v8\|Stage IVA Colorectal Cancer AJCC v8\|Stage IVA Major Salivary Gland Cancer AJCC v8\|Stage IVA Uterine Corpus Cancer AJCC v8\|Stage IVB Colon Cancer AJCC v8\|Stage IVB Colorectal Cancer AJCC v8\|Stage IVB Major Salivary Gland Cancer AJCC v8\|Stage IVB Uterine Corpus Cancer AJCC v8\|Stage IVC Colon Cancer AJCC v8\|Stage IVC Colorectal Cancer AJCC v8\|Stage IVC Major Salivary Gland Cancer AJCC v8\|Unresectable Colorectal Carcinoma\|Unresectable Gastroesophageal Junction Adenocarcinoma\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 5 2021	Phase 1
NCT04361825	Enrolling by invitation	Drug: Durvalumab	Small Cell Lung Cancer	Samsung Medical Center\|AstraZeneca	June 17 2020	Phase 2
NCT04298008	Recruiting	Drug: AZD6738\|Drug: Durvalumab	Bile Duct Cancer\|Chemotherapy Effect	Seoul National University Hospital	June 25 2020	Phase 2
NCT04298021	Recruiting	Drug: AZD6738\|Drug: Durvalumab\|Drug: Olaparib	Bile Duct Cancer\|Chemotherapy Effect	Seoul National University Hospital	June 25 2020	Phase 2
NCT03669601	Recruiting	Drug: AZD6738\|Drug: Gemcitabine	Cancer	CCTU- Cancer Theme\|AstraZeneca\|Cambridge University Hospitals NHS Foundation Trust	October 15 2019	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

定制您的化合物库

Ceralasertib (AZD6738)

客户使用Selleck生产的Ceralasertib (AZD6738)发表文献67篇：

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ceralasertib (AZD6738) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

ATM/ATR Signaling Pathway Map

相关ATM/ATR产品